FDA Under Fire: Rare Liver Disease Patients Demand Regulatory Reform

DENVER, CO – October 28, 2026 – The intersection of regulatory bureaucracy and terminal illness has reached a boiling point for the rare disease community. Following the U.S. Food and Drug Administration's (FDA) Rare Disease Framework public meeting today, patient advocacy group PSC Partners Seeking a Cure issued a stark call to action, demanding that federal regulators translate bureaucratic dialogue into immediate, decisive reforms. At the heart of the conflict is primary sclerosing cholangitis (PSC), a relentless and potentially fatal liver disease that currently has zero FDA-approved therapeutic treatments proven to slow, halt, or reverse its progression.

Characterized by chronic inflammation and severe scarring of the bile ducts, PSC causes progressive liver damage that places patients at high risk for liver failure and certain cancers. Despite the severity of the condition, drug developers have repeatedly struggled to navigate the FDA's evidentiary standards. The resulting friction between regulatory caution and the urgent needs of patients has highlighted systemic flaws in how the pharmaceutical industry and federal overseers approach rare disease innovation.

As of this year, only approximately five percent of recognized rare diseases have an FDA-approved treatment. For the tens of thousands of patients living with PSC globally, the lack of commercial therapies means relying on symptom management and waiting for eventual organ failure. Advocacy groups are now arguing that the regulatory process itself has become a barrier to scientific breakthrough, prompting a nationwide push for regulatory flexibility, clearer approval pathways, and the integration of patient risk-tolerance data into federal therapy evaluations.

The Regulatory Gauntlet: Why Biopharma Is Walking Away

Developing drugs for rare diseases is inherently difficult due to small, heterogeneous patient populations and poorly understood natural disease progressions. However, for PSC specifically, the regulatory gauntlet has proven uniquely devastating to commercial investment. Industry analysts note that drug sponsors frequently face shifting regulatory goalposts between the initiation of clinical studies and formal review, resulting in delayed treatments and, in many cases, entirely abandoned research programs.

One of the primary hurdles is the difficulty in identifying clear, early clinical endpoints that the FDA will accept as reliable predictors of long-term clinical benefit. In PSC trials, researchers have historically relied on surrogate endpoints, such as fluctuating levels of alkaline phosphatase in the blood. However, the correlation between these biomarkers and hard clinical outcomes—like transplant-free survival—has been hotly debated by regulators. This ambiguity creates a high-risk environment for biotech executives and life science investors. When the criteria for success remain undefined or subject to change mid-trial, pharmaceutical companies are increasingly forced to shelve promising therapies.

In an attempt to address these systemic failures, the FDA launched its Rare Disease Framework Initiative earlier this month, aiming to replace a uniform review approach with frameworks tailored to individual rare diseases. Furthermore, the agency's Rare Disease Evidence Principles, announced late last year, were designed to clarify how flexible evidentiary standards could be applied to ultra-rare conditions. While one senior regulatory official emphasized that the agency aims to design a scheme that stands the test of time, advocates argue that the pace of reform is failing the patients who are currently running out of time.

Risking Harm to Save Lives: When Patient Urgency Outpaces FDA Caution

The fundamental tension stalling PSC drug development lies in the disparity between the FDA's bureaucratic safety thresholds and the risk tolerance of terminal patients. Regulators are tasked with ensuring that experimental drugs do not cause undue harm, but for patients facing a fatal disease with no available treatments, the definition of "acceptable risk" is vastly different.

A recent global survey of more than 1,100 PSC patients and caregivers, conducted by PSC patient organizations, starkly illustrated this divide. The data revealed that the vast majority of patients are willing to accept substantial, invasive monitoring burdens—including routine liver biopsies, frequent blood tests, and extensive clinic visits—simply to gain access to experimental, disease-modifying therapies. These findings suggest that patients are eager to accept unknown risks to improve their quality of life and survival odds, a perspective that advocates say is routinely marginalized in federal risk-benefit analyses.

“For people living with PSC and their families, the need for new treatment options cannot be overstated,” said Ricky Safer, Founder and CEO of PSC Partners. “Patients deserve a driving voice in the development and review of the treatments that will dictate their futures. We need a regulatory and research environment that aggressively fosters innovation while maintaining rigorous safety standards.”

Patient advocacy groups have been active partners in discussions with clinicians and regulators since 2015, even hosting a patient-led, FDA-sponsored Patient-Focused Drug Development meeting in 2020. Despite these efforts, the integration of patient preference studies into actual regulatory decision-making remains inconsistent. Advocates are now pressing the FDA to embed the patient voice at clearly defined milestones throughout the drug review process, ensuring that the people bearing the ultimate consequences of regulatory delays have a say in the risks they are allowed to take.

Beyond the Scalpel: Why Organ Transplants Are a Flawed Fix

With pharmaceutical pipelines stalled, the only definitive intervention for end-stage primary sclerosing cholangitis remains a liver transplant. However, relying on organ transplantation as the sole viable treatment option places a severe and unsustainable burden on both patients and the broader healthcare system.

A transplant is a measure of absolute last resort, contingent upon a patient surviving long enough on the United Network for Organ Sharing (UNOS) waitlist for a donor organ to become available. Even when a liver is secured in time, the surgical intervention is not a cure. Post-transplant care presents its own severe, lifelong health challenges, including reliance on immunosuppressant drugs and vulnerability to serious infections.

Most alarmingly, clinical data shows that PSC recurs in the new, transplanted liver in approximately 40 percent of patients. This high recurrence rate means that many patients will eventually face a second organ failure, necessitating re-transplantation. This cycle not only devastates patient outcomes but also severely depletes the critically limited supply of life-saving donor organs available for other patients on the national waitlist. The acute systemic strain caused by PSC highlights the urgent, cascading need for disease-modifying therapies that can halt the disease before a transplant becomes necessary.

Forging a "Fit-for-Purpose" Path Forward

As the FDA continues to solicit public feedback on its Rare Disease Framework Initiative through December, the biotechnology sector and patient communities are watching closely. The proposed policy shifts promise clearer decisions, wider use of outside experts, and support for novel trial designs, including platform trials and real-world evidence methodologies.

A director within the FDA's rare disease division recently noted publicly that the new framework is expected to improve predictability for sponsors and patients alike, acknowledging that a tailored approach is necessary for small populations. However, for organizations like PSC Partners, promises of future efficiency must be met with immediate, sustained commitments of resources to rare disease research and FDA oversight.

The demand from the rare liver disease community is clear: funding constraints and bureaucratic hesitation must never delay the development of life-saving therapies. As medical technology and genetic understanding advance at an unprecedented rate, the regulatory apparatus governing these innovations must evolve in tandem. For the tens of thousands of patients living with PSC, bridging the gap between scientific potential and regulatory approval is not just a matter of policy—it is a matter of survival.